The outlook of companies tied to Viagra's past presents a complex investment landscape. While the initial success generated substantial gains, generic competition have significantly diminished revenue. Investing in connected pharmaceutical companies now requires a careful assessment of proprietary rights , evolving healthcare shifts , and the possi